ALSP Orchid Acquisition Corporation I
Status: Liquidated
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $172.50M |
|---|---|
| IPO Date | Nov 19, 2021 |
| CEO | Thong Q. Le |
| Left Lead | Stifel Nicolaus |
| IPO Cash in Trust | 102.0% |
| SPAC Tenor | 15 + 6 + 3 + (3) |
| IPO Sector |
Healthcare
Life science companies in North America and Singapore with a particular emphasis on companies developing assets and next-generation platform technologies with broad applicability |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Feb 17, 2023 |
| Closing Date | Nov 15, 2023 |
ALOR
ALORU
ALORW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on ALSP Orchid Acquisition Corporation I:
- Structure and cap table
- 10 directors & officers
- 12 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Thong Q. Le | 45 | CEO, President and Director |
| Ian A. W. Howes | 63 | CFO and Director |
| Kendall M. Mohler, Ph.D. | 65 | Chief Development Officer |
| Andras T. Forgacs | 45 | Chief Operating Officer |
| Kevin T. Chow, Ph.D. | 51 | Chief Business Officer |
| Bruce L.A. Carter, Ph.D. | 78 | Chairman of the Board of Directors |
| Mark W. Hahn | 59 | Director Committee Chair |
| Sundar R. Kodiyalam | 59 | Director |
| Stephanie C. Read | 45 | Director |
| Eugene W. Yeo, Ph.D. | 44 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Stifel Nicolaus | Joint BR | 9,750,000 | units |
| Nomura | Joint BR | 5,250,000 | |
| 15,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.